Kornimate/medical-research-clean huggingface dataset:
fluorescence-navigated thoracoscopy for detection of small pulmonary nodules

Conditions: Pulmonary Nodule, Solitary; Pulmonary Nodule, Multiple

Summary: fluorescence-navigated thoracoscopic imaging with indocyanine green (icg) is a novel technique for detection of small pulmonary nodules other than traditional radiography or intraoperative palpation. as a non-targeted fluorescent contrast agent, icg accumulates in tumors by the enhanced permeability and retention effect (epr), making the lesions fluoresce under fluorescent imaging. however, the optimal dosage and injection time of icg are still under exploration. hence, we perform this study in humans made up of four groups to determine the optimal time and dose.


Eligibility criteria:
inclusion criteria: * peripheral pulmonary solid nodules, with diameter 1-3 cm. * suitable for surgery and signed informed consent. exclusion criteria: * liver dysfunction. * allergic to indocyanine green. * can't tolerate thoracoscopic surgery.
combination treatment for posttraumatic stress disorder (ptsd) after the world trade center (wtc) attack

Conditions: Posttraumatic Stress Disorder

Summary: this randomized controlled trial evaluates efficacy of combined prolonged exposure (pe) and the selective serotonin reuptake inhibitor (ssri) paroxetine in the treatment of survivors of the world trade center (wtc) attacks.

selective serotonin reuptake inhibitor (ssri) medication is often recommended in combination with cognitive behavioral therapies for ptsd, but combined initial treatment of ptsd has not been studied under controlled conditions. also, there are few studies of either treatment in survivors of terrorism. this randomized controlled trial evaluates efficacy of combined prolonged exposure (pe) and the ssri paroxetine in the treatment of survivors of the world trade center (wtc) attacks.

Eligibility criteria:
inclusion criteria: * posttraumatic stress disorder, chronic, related to world trade center attacks * age 18-70 * caps score greater than 45 * willingness to consent * for women, negative pregnancy test and using adequate birth control exclusion criteria: * prominent suicidal ideation * current psychotic disorder * unstable medical illness * women who are pregnant or nursing mothers * alcohol or substance use disorder in the past 3 months * history of seizure disorder * conditions that contraindicate use of paroxetine * inability to tolerate a drug free period prior to beginning the study of 4 weeks for maois or fluoxetine and 2 weeks for other psychotropic drugs, except zolpidem for insomnia.

Keywords: ptsd anxiety disorders trauma
clinical performance evaluation of two daily disposable silicone hydrogel toric contact lenses

Conditions: Refractive Errors

Summary: the purpose of this study is to evaluate the rotational behavior of dt1 toric contact lenses.

this is a single visit, non-dispense study where subjects will be exposed to the test and control lenses for approximately 1 hour each.

Eligibility criteria:
inclusion criteria: * current wearer of any commercial soft daily wear contact lens with at least 3 months of wearing experience with a minimum wearing time of 5 days per week and 8 hours per day. * requiring contact lens (manifest refraction) of a cylindrical power of -0.75 to -2.50 diopter cylinder (dc). * best corrected distance visual acuity 20/25 or better snellen in each eye (as determined by manifest refraction at screening). * willing to not use rewetting/lubricating drops at any time during the study. other protocol-defined inclusion criteria may apply. exclusion criteria: * any anterior segment infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator. * any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator. * history of refractive surgery or plan to have refractive surgery during the study or irregular cornea in either eye. * eye injury in either eye within 12 weeks immediately prior to enrollment for this trial. other protocol-defined exclusion criteria may apply.

Keywords: toric contact lens daily disposable silicone hydrogel contact lens axis orientation astigmatism
toetva feasibility and complications - single center first experience

Conditions: Thyroid Gland Disease; Surgery

Summary: all participants who underwent (or will undergo) a transoral endoscopic thyroidectomy via vestibular approach (toetva) at the investigators' center are observed for complications and feasibility of this surgery. anonymised data relevant to the participants' condition will be used.


Eligibility criteria:
inclusion criteria: * patients who underwent (or will undergo) a transoral endoscopic thyroidectomy via vestibular approach (toetva) at the investigators' center exclusion criteria: * patients who did not undergo (or will not undergo) a toetva at the investigators' center

Keywords: toetva notes surgery endocrine thyroid case series
robotic intervention framework for children with autism spectrum disorder to enhance social engagement and participation

Conditions: Autism Spectrum Disorder; Social Engagement; Robotic Intervention

Summary: this study will develop and test a robotic intervention framework for children with asd in the real context. the first part of this study will focus on the identification and initial testing of core elements of effective robotic intervention programs to form a practice framework. pat ii will use a randomized control trial to test the efficacy of the robotic intervention programs that incorporated all elements of the framework. part iii will use a qualitative approach to examine the qualitative outcomes of the program with reference to the elements of the practice framework. with a framework that is built upon evidence and tested sufficiently, practice guidelines and intervention protocol will be delineated to ensure success of robotic intervention programs.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of autism spectrum disorder * aged between 5-11 * normal intelligence exclusion criteria: * with self-injurious or aggressive behavior * with hearing or visual impairment
comparison of the effect of intravenous and perineural dexmedetomidine in gastric cancer surgery

Conditions: Gastric Cancer; Pain, Postoperative

Summary: using random case assignment to investigate the analgesic and sedative effect of intravenous dexmedetomidine and dexmedetomidine as a local anesthetic adjuvant in ultrasound-guided subcostal tap block in gastric cancer patient undergoing gastrectomy or partial gastrectomy.

the process of the experiment (brief describe) the participant patients will be randomly allocated into three groups: the intravenous dexmedetomidine group (dex_iv group), dexmedetomidine adding to local anesthetic as an adjuvant for subcostal tap block (dex_adj group), and control group. all patients receive gastrectomy or partial gastrectomy in general anesthesia as standard. thirty minutes before the end of surgery, the patients in dex_iv group receive 0.5mcg/kg dexmedetomidine infusion for 30 minutes, while the patients in dex_adj group and control group receive 0.125ml/kg 0.9% normal saline iv infusion for 30 minutes. all patients have ultrasound-guided tap block single injection after the end of surgery and before the tracheal tube extubation. the block agents in dex_adj group is 40 ml of 0.375% ropivacaine with 0.5mcg/kg dexmedetomidine, while in dex_iv group and control group are only 40ml of 0.375% ropivacaine. the iv pca pump will be set up before patients awaken in the post-anesthesia care unit. all patients are assessed for the signs of emergence agitation with riker sedation-agitation scale in the post-anesthesia care unit. the numerical rating scale (nrs) for pain intensity assessment, the opioid consumption via iv pca pump, and the patients satisfaction will be documented for postoperative 3 days for the impact evaluation of dexmedetomidine in postoperative analgesia in patients undergoing gastric cancer surgery with subcostal tap block.

Eligibility criteria:
inclusion criteria: * gastric cancer patients undergoing gastrectomy or partial gastrectomy, who receive ultrasound-guided subcostal tap block and pca for postoperative analgesia exclusion criteria: * surgery involved other visceral organ (eg. combined splenectomy or partial hepatectomy), patients with histories of adverse drug reaction to dexmedetomidine, bradycardia (baseline heart rate \<60 beats/min), any type of atrioventricular block in electrocardiogram (ekg), heart failure, significant renal or hepatic impairment, severe bronchopulmonary disease, any coagulant disorder, and pregnant or breast-feeding woman.

Keywords: subcostal transversus abdominis plane block
immunologic response of hepatitis b vaccine

Conditions: Hepatitis B

Summary: this study aims to evaluate the immunologic response to the two hepatitis b virus (hbv) vaccination booster strategies in previously vaccinated hiv-infected adults at maharaj nakorn chiang mai hospital.

this study intended to evaluate the immunologic response to the two hepatitis b virus (hbv) vaccination strategies in previously vaccinated hiv-infected adults at maharaj nakorn chiang mai hospital. as a part of hbv prevention program, hbv vaccine has been included in thailand expanded program on immunization (epi) since 1992. hbv vaccine has been shown to be safe, effective, and has a prolonged protective immunity to hbv infection. despite the immunity from hbv vaccination could wane overtime, the previous data in general population revealed that hbv vaccine booster could raise the immune in very well. however, the data about booster effects for hbv vaccine among hiv-infected population who previously received a vaccination during their childhood is lagging. based on previous data of vaccination response in hiv-infected population, the investigators estimate that the protective antibody will rise up to 60% with hbv vaccine one dose booster versus 90% with 3-dose series. eighty participants, hiv-infected person who were born after hbv vaccine were born after hbv has been included in thai epi without evidence of hbv infection nor protective immunity, will be enrolled to this study (with estimation of 5% loss follow up rate). the participants will be randomized in 1:1. the immune response and vaccine safety will be evaluated at 1,7 and 12 months after the first dose hbv vaccine.

Eligibility criteria:
inclusion criteria: * document of hiv infection * thai nationality * age ≥18 years old * born after 1 january 1992 * has been taking antiretroviral drugs for hiv treatment * cd4 ≥200 cell/mm3 and vl \<50 copies/ml for at least 6 months before enrollment * negative for any hbv and hcv serological markers * willing to sign informed consent * able to follow up exclusion criteria: * active opportunistic infection * pregnancy or breast feeding * history of previous hepatitis b vaccine booster * history of hypersensitivity to any component of vaccine * malignancy which received chemotherapy or radiation * immunocompromised condition such as solid-organ transplantation, chemotherapy in the last 6 months * on immunosuppressive treatment, immunomodulating treatment or general corticotherapy (equal or above 0.5 mg per kg per day ) * renal failure (creatinine clearance \<30 ml/min) * transaminitis in the past 3 months (≥ 5 unl) * decompensated cirrhosis (child-pugh class c) * unable or not willing to return for follow up

Keywords: hbv vaccination immunity
test of a new gel-based colon cleansing agent compared to moviprep

Conditions: Pharmacological Action

Summary: crossover study comparing moviprep (for bowel cleansing) with a new gel-based colon cleansing agent before colonoscopy

crossover study comparing moviprep (for bowel cleansing) with a new gel-based colon cleansing agent before colonoscopy. study performed in health subjects.

Eligibility criteria:
inclusion criteria: - healthy exclusion criteria: * allergy to content of products
prediction of bleeding in placenta previa

Conditions: Placenta Previa Bleeding

Summary: to assess the ability of clinical and sonographic variables to predict the need of blood transfusion \> 4 units of packed rbcs in women undergoing cesarian section for placenta previa .

womenwith placenta previa after 32 weeks will be assessed for participation if they are eligible an adequate data will be taken : - clinical factors : including maternal age, abortion history, cesarean section history, gestational age at delivery, whether the operation will be carried out as an emergency surgery, and whether bleeding has started before the operation, will evaluated. the number of abortion history will be counted only if a dilatation and curettage was performed. preoperative hemoglobin and hematocrit values will be checked. the amount of prbcs transfused during operation will be measured. -ultrasonographic factor: adiagnosis of placenta previa was made when the placenta covered the internal orifice of the cervix after 32 weeks' gestation. we will check for the presence of a hypoechoic area between the myometrium and the placenta. the vascularity of the placenta will be classified as normal or hypervascular on color doppler imaging. we will examine the location of placenta ( anterior . posterior. anterior with lateral deviation. posterior with lateral deviation) and presence ofintraplacental lacunae (an irregular area of low echogenicity larger than 1 cm × 1 cm in the placental parenchyma) * intraoperative factor: assess surgeon years of experience management plan hemostatic sutures other conservative management hysterectomy (primary or secondary) assessment of amount of blood taken in 24 h from operation

Eligibility criteria:
inclusion criteria: * women with placenta previa after 32 weeks * women with placenta accreta after 32 weeks exclusion criteria: * abruption placenta * unavilable or limited avilability of blood group
a prospective multi-center study of anterior lens capsulotomy using the mynosys zepto system

Conditions: Cataract

Summary: this study will evaluate outcome in subjects who have elected to have zepto capsulotomies during cataract surgery with phacoemulsification.

this study will evaluate outcome in subjects who have elected to have zepto capsulotomies during cataract surgery with phacoemulsification to evaluate safety and effectiveness. the primary effectiveness endpoint is a complete capsulotomy in at least 95 percent of the cases. the primary safety endpoint is posterior capsular rupture and virtuous loss in 4 percent or less of the subjects. other parameters to be captured during the study include anterior capsule tears, corneal touch, capsulotomy diameter, contraption of the zepto capsulotomy, size of the corneal incision pre and post zepto, interocular lens contraption and evaluation of zonular stability and the incidence and severity of adverse events. the criteria for patient success will be accessed based on the successful completion of a 360 degree capsulotomy without tissue bridges and no posterior capsule rupture and vitreous loss. the criteria for study success will be accessed based on a greater than or equal to 95 percent of the cases having a complete 360 degree capsulotomy without tissue bridges and less than 4 percent of subjects with posterior capsule rupture and vitreous loss.

Eligibility criteria:
inclusion criteria: 1. subjects must be age 22 or older, 2. subjects consenting to undergoing phacoemulsification and iol implant surgery for the treatment of symptomatic age related lens cataract, and then electing to undergo zeptotm capsulotomy, 3. subjects must be willing and able to return for scheduled treatment and follow-up examinations for 3 months. exclusion criteria: 1. disease or pathology in the treatment eye that will compromise visual performance or refractive outcome (e.g. previous refractive surgery), 2. zonular abnormality, 3. posterior polar cataract, 4. fellow eye with acuity less than 20/200, 5. any prior ocular surgery of the study eye, 6. pupillary dilation during the pre-operative exam of less than 7 mm in diameter, 7. proliferative diabetic retinopathy, 8. disorders of the ocular muscles, such as nystagmus or strabismus, 9. chronic uveitis, 10. abnormal corneal endothelium, 11. subjects on medications with, in the opinion of the surgeon, significant ocular side effects, 12. pregnant or nursing (lactating) women, 13. implanted ocular device or drug in the study eye, 14. any other condition, which in the judgment of the investigator would prevent the subject from completing the study (e.g. documented diagnosis or treatment for symptoms associated with dementia, mental illness), 15. current participation in another drug or device clinical study, or participation in such a clinical study within the six months.
study on the effect of a physical training structured program after a pulmonary thromboembolism

Conditions: Pulmonary Embolism

Summary: exercise training, as the core component of a pulmonary rehabilitation program, may help restore arterial blood flow in the lungs of patients who had suffered pulmonary embolism (pe), stimulating and promoting vasodilator effects, repairing the damaged endothelium and recruiting new blood vessels and also inducing a net fibrinolytic balance. besides, exercise training could have a positive effect on quality of life of these patients.

an experimental multicenter study is proposed , randomized according to parallel assignation and blinded to third ones to evaluate the effect of a 10-weeks structured exercise-based intervention protocol on the restoration of lung blood flow after an acute pe. main objective is to compare the efficacy and safety in terms of quantitative measures from lung scintigraphy, of lung perfusion versus usual care in patients with pe. additionally the study is aimed to identify bio-markers of response to treatment (mrnas, mps and proteomic approach) and to analyze the effects of training on exercise capacity, quality of life parameters and anxiety depression scores.

Eligibility criteria:
inclusion criteria: patients 18 years or older at pe diagnosis pe diagnosis confirmed by imaging tests according guidelines patients under correct anticoagulant treatment persistent lung perfusion defects at one month after pe diagnosis. signed consent inform exclusion criteria: incidental or silent pe pregnant or puerperal woman life expectancy less than 6 months severe comorbidities (nyha 4 in severe heart failure; copd, gold d; severe psychiatric illness) any disability for physical exercise according to their doctors -

Keywords: venous thromboembolic disease pulmonary embolism rehabilitation program exercise training
bacterial interference for preventing recurrent urinary tract infection - new ways of treatment

Conditions: Recurrent Urinary Tract Infections

Summary: urinary tract infection (uti) is one of the most common bacterial infections worldwide. it affects 150 million people annually. treatment of patients with uti entails a high consumption of antibiotics and large social and health costs. with this protocol, we want to elucidate alternative treatment methods for especially recurrent urinary tract infection. bacteria have internal competitiveness (bacterial interference) and it is known that the non-pathogenic e.coli can outcompete the pathogenic e.coli in laboratory studies. we intend to strengthen the clinical evidence that it can be used as patient treatment through a clinical, placebo-controlled, double-blind trial at odense university hospital.

urinary tract infection (uti) is one of the most common bacterial infections worldwide. it affects 150 million people annually. treatment of patients with uti entails a high consumption of antibiotics and large social and health costs. with this protocol, we want to elucidate alternative treatment methods for especially recurrent urinary tract infection. bacteria have internal competitiveness (bacterial interference) and it is known that the non-pathogenic e.coli can outcompete the pathogenic e.coli in laboratory studies. we intend to strengthen the clinical evidence that it can be used as patient treatment through a clinical, placebo-controlled, double-blind trial at odense university hospital. claim to be investigated: * the non-pathogenic bacterial strain (abu) e.coli can overcome the most common pathogenic e.coli (upec) in humans. * abu can be used for preventive treatment in patients with recurrent urinary tract infections. clinical effect of preventive treatment (prophylactic treatment) with the non-pathogenic bacterial strain (abu) in a selected group of patients with recurrent cystitis: a clinical, placebo-controlled, triple-blinded study.

Eligibility criteria:
inclusion criteria: * diagnosed with recurrent cystitis including 2 times of ruti within the last 6 months or 3 times in the last 12 months, where at least 2 cultures show the same bacteria. * normal investigation for lower urinary tract diseases (lutd) including voiding diary, symptom scores, flexible cystoscopy, voiding diagram and test for residual urine. * failed previously treatments. * patients with native bladder with both spontaneous voiding, the need for clean intermittent catheter (cic) or indwelling catheter. * patients with neurogenic and non-neurogenic bladder dysfunction. * patients with urostomy, kidney transplantation or another complicated genesis. * written consent. exclusion criteria: * malignancy in the urinary tract, kidney-, ureteral- or bladder stones, age \< 18 years, pregnancy, breastfeeding. patients in ongoing orally antibiotic treatment. not able to speak or understand danish.

Keywords: ruti e.coli prophylactic bladder lavage
skin sympathetic nerve activity and cardiac arrhythmia

Conditions: Sudden Death; Ventricular Tachycardia; Persistent Atrial Fibrillation

Summary: sympathetic tone is important in cardiac arrhythmogenesis. the simultaneous recording of sympathetic nerve activity (sna) and electrocardiogram (ecg) was obtained by invasive method. the purpose of this protocol is to further develop this recording method to turn it into a new non-invasive tool for arrhythmia prediction and detection. this method may also be useful in validating the results of surgical procedures aimed at sympathetic denervation


Eligibility criteria:
inclusion criteria: - patient hospitalized at bordeaux university hospital for sudden death, ventricular tachycardia, persistent or paroxysmal atrial fibrillation treated by ablation and/or vein of marshall ethanol infusion exclusion criteria: * pregnancy, * patient under 18 year old, * patient with a cardiac stimulation device

Keywords: skin sympathetic nerve activity (skna) electrocardiogram (ecg) cardiac arrythmia